Recent reviews further emphasize that PKM2 is upregulated within the inflammatory microenvironment of chronic liver diseases—including viral hepatitis, alcohol-related liver disease, and NAFLD—where it contributes to glycolytic reprogramming and immune regulation [1,47]. Here, PKM is linked to metabolic dysfunction-associated steatotic liver disease.